0000000000417561

AUTHOR

Etienne Caron

showing 4 related works from this author

An open-source computational and data resource to analyze digital maps of immunopeptidomes

2015

We present a novel mass spectrometry-based high-throughput workflow and an open-source computational and data resource to reproducibly identify and quantify HLA-associated peptides. Collectively, the resources support the generation of HLA allele-specific peptide assay libraries consisting of consensus fragment ion spectra, and the analysis of quantitative digital maps of HLA peptidomes generated from a range of biological sources by SWATH mass spectrometry (MS). This study represents the first community-based effort to develop a robust platform for the reproducible and quantitative measurement of the entire repertoire of peptides presented by HLA molecules, an essential step towards the de…

Databases FactualimmunopeptidomeQH301-705.5Systems biologyScienceImmunologyComputational biologyBiologyBioinformaticsMass spectrometryGeneral Biochemistry Genetics and Molecular BiologyMass Spectrometry03 medical and health sciencesResource (project management)Fragment (logic)HLA Antigenstargeted mass spectrometryHigh-Throughput Screening AssaysDIAhumanAntigenshuman leukocytes antigenBiology (General)030304 developmental biology0303 health sciencesAntigen PresentationGeneral Immunology and MicrobiologyDigital mappingGeneral Neuroscience030302 biochemistry & molecular biologyQRComputational BiologyGeneral Medicine3. Good healthTools and ResourcesHigh-Throughput Screening AssaysWorkflowTargeted mass spectrometrySWATH-MSMedicinePeptidesComputational and Systems BiologyeLife
researchProduct

Author response: An open-source computational and data resource to analyze digital maps of immunopeptidomes

2015

Open sourceResource (project management)DatabaseDigital mappingComputer sciencecomputer.software_genrecomputer
researchProduct

Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE)

2018

Minimal Information about an Immuno-Peptidomics Experiment (MIAIPE) is an initiative of the members of the Human Immuno-Peptidome Project (HIPP), an international program organized by the Human Proteome Organization (HUPO). The aim of the MIAIPE guidelines is to deliver technical guidelines representing the minimal information required to sufficiently support the evaluation and interpretation of immunopeptidomics experiments. The MIAIPE document has been designed to report essential information about sample preparation, mass spectrometric measurement and associated mass spectrometry (MS)-related bioinformatics aspects that are unique to immunopeptidomics and may not be covered by the genera…

Proteomics0301 basic medicineComputer scienceComputational biologyProteomicsBiochemistrySpecimen Handling03 medical and health sciencesStandardisation & GuidelinesHuman proteome projectHumansantigen processing and presentationDatabases ProteinMolecular Biology030102 biochemistry & molecular biologyHistocompatibility Antigens Class IHistocompatibility Antigens Class IIimmunopeptidomicsComputational BiologyMass spectrometricPeptide Fragmentsmajor histocompatibility complex3. Good health030104 developmental biologyComputational Biology/standards; Databases Protein; Histocompatibility Antigens Class I/analysis; Histocompatibility Antigens Class I/immunology; Histocompatibility Antigens Class I/metabolism; Histocompatibility Antigens Class II/analysis; Histocompatibility Antigens Class II/immunology; Histocompatibility Antigens Class II/metabolism; Humans; Peptide Fragments/analysis; Peptide Fragments/immunology; Peptide Fragments/metabolism; Proteomics/standards; Software; Specimen Handling/standards; antigen processing and presentation; immunopeptidomics; major histocompatibility complexSoftwareantigen processing and presentation; immunopeptidomics; major histocompatibility complex
researchProduct

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

2017

International audience; TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, …

TuberculosiImmunologybacille Calmette–Guérin610 Medicine & healthReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesTuberculosis; Bacille Calmette-Guérin; Vaccination; Biomarker; Clinical trial; Portfolio management; Discovery[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Immunology and AllergyBacille Calmette-Guérinbacille Calmette-Guérinbacille Calmette-Guerin2403 Immunology10179 Institute of Medical MicrobiologyBacille Calmette-Guérin; Biomarker; Clinical trial; Discovery; Portfolio management; Tuberculosis; Vaccination; Immunology and Allergy; Immunologyclinical trialvaccination[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticstuberculosis2723 Immunology and Allergy570 Life sciences; biologybiomarkerportfolio managementdiscovery
researchProduct